Distinct gut microbial profile may identify pancreatic cancer, irrespective of stage

Pancreatic (blue) cancer cells grow as part of the membranes (red). Credit: National Cancer Institute

A specific group of colon cancers can detect pancreatic cancer, regardless of how the disease progresses, according to a study published online in the journal. Gut.

The results of the study offer hope for a new, non-invasive way of diagnosing the disease, which is currently relying on methods to diagnose it, the researchers said.

Pancreatic cancer is the 12th most common common cancer all over the world, but it will be a common occurrence in the next two years. The most common type of disease is pancreatic ductal adenocarcinoma which idea is not good, with less than 1 in 20 of the victims living 5 years or more.

This is because the diagnosis is often made when the disease progresses and because of poor treatment options. Scans, tissue samples, and urine as well blood sample are used to assess it. But there are small steps that can be taken, and in the first instance, there is an urgent need, say the researchers.

Recent evidence suggests that changes in the microbiome – trillions of bacteria, fungi, and other microorganisms that live in the digestive tract – may have an impact on growth and development.

To further investigate this, the researchers analyzed 100 spit and 212 stool samples and pancreatic tissue from 57 Spanish elderly diagnosed with ductal and pre-treatment with-25 with primary and 32 subtypes with coronary heart disease. rising; 50 healthy people matched age and sex; and 29 people suffering from chronic bowel disease, a known risk factor for pancreatic cancer.

Gut microbes are more informative than micro-organisms. After calculating known risk factors such as smoking, smoking, obesity and diabetes, specific pathological data were observed in stool samples of people with pancreatic cancer compared to people with current pancreatitis. kidneys and those without any disease.

Engineering techniques have identified the behavioral characteristics of some species and the shortcomings of others. Methanobrevibacter smithii, Fusobacterium nucleatum, Alloscardovia omnicolens, Veillonella atypica and Bacteroides finegoldii were abundant in the stool samples of cancer patients while Faecalibacterium prausnitzii, Bacteroides coprocola, Bifidobacterium.

This microbiome profile continues to identify patients with the disease, regardless of the progress made indicating that the signature microbiome may emerge early and the stool microbiome may infection at an early stage, the researchers said.

Predictive power was calculated using the area under the optical receiver operating mode (AUROC), a graphical representation of how the test evaluates and classifies the given conditions. An area below the ROC threshold of 0.5 corresponds to the random potential; 1 equals absolute accuracy. In this case, the AUROC accuracy is 0.84.

The consistency increased still to 0.94 when the microbial profile was combined with blood levels of antigen 19-9’s carbohydrate, an indicator of pancreatic cancer, but also with different conditions, and only the test did not of abuse, approved by the U.S. Department of Medicine. , Food and Drug Administration (FDA), to monitor the progression of pancreatic cancer.

The ability to detect micro-organisms was confirmed in a group of 76 Germans, 44 of whom had pancreatic cancer and 32 of whom did not.

It was later based on public data from 25 studies involving 5792 samples covering 9 different health conditions, including some cancers and type 2 diabetes. a risk factor for pancreatic cancer.

The details of the oral mucosa, stool, and pancreatic tissue samples of patients with pancreatic ductal cancer were similar, suggesting that they could be closely linked.

“Our data are very observant and varied,” they highlight the researchers. “However, there are strong indications that fecal microbiome changes are not only the result of pancreatic damage or its effects, although the direct effects cannot be ruled out,” they said.

And they go so far as to say that given previous research on the possible link between pancreatic cancer and gut microbiome, ”we believe that the committee presented. [ductal pancreatic cancer]]related strains may be more appropriate than used for diagnosis, providing future implications for disease prevention and treatment. “

In the related commentary, Drs. Rachel Newsome and Christian Jobin, of the University of Florida, cautioned: “Although promising, these findings are clinically limited due to the nature of the research component, so predictive indicators will need to be tested using a team that will be reached before it is achieved. ultimately on their clinical impact. “

Further research will be needed to find out if the bacterial data are specific to pancreatic cancer and are not isolated from other types of cancer, they added.

However, the study “represents an important contribution to the development of predictive indicators for [ductal pancreatic cancer] and highlights the important role of microbiota in cancer control …… ”and represents a major development for non-cancer patients. cancer discovery, ”they wrote.

The use of routine clinical data may predict the risk of pancreatic cancer

Learn more:
Significance of faecal microbiota with specificity for pancreatic cancer, Gut (2022).

hint: Variations in small intestine data can detect pancreatic cancer, regardless of stage (2022, March 8) retrieved 8 March 2022 from 03-distinct-gut-microbial-profile-pancreatic.html

This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, any part may not be reproduced without our written permission. Content is provided for informational purposes only.

Distinct gut microbial profile may identify pancreatic cancer, irrespective of stage Source link Distinct gut microbial profile may identify pancreatic cancer, irrespective of stage

Related Articles

Back to top button